The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma

Current Opinion in Oncology

Volumn 21, Issue 5, 2009, Pages 397-400

  Maeda, Lauren S ^a   Advani, Ranjana H ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Nodular lymphocyte predominant Hodgkin lymphoma; Rituximab; T cell rich B cell lymphoma

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; FOLLOW UP; HUMAN; MONOTHERAPY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTES; TREATMENT OUTCOME;

EID: 69549137040     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832f3ca3     Document Type: Review

References (19)

1. Harris NL, Jaffe ES, Stein H, et al. A Revised European-American Classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361. (Pubitemid 24273002)
2. Stein H, Swerdlow SH, Campo E, et al. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed Lyon, France: IARC Press; 2008.
3. Jaffe E, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. pp. 240-243.
4. Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 2008; 205:2251-2268.
5. Rüdiger T, Gascoyne RD, Jaffe ES, et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol 2002; 13:44-51. (Pubitemid 34567401)
6. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma project on lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1999; 17:776-783. (Pubitemid 29109305)
7. Franklin J, Tesch H, Hansmann ML, et al. Lymphocyte predominant Hodgkin's disease: pathology and clinical implication. Ann Oncol 1998; 9:39-44. (Pubitemid 29049116)
8. Tsai H, Mauch P. Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Radiat Oncol 2007; 17:184-189.
9. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection - a study of the French Society of Pediatric Oncology. J Clin Oncol 2003; 15:2948-2952. (Pubitemid 46621846)
10. Nogová L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26:434-439. (Pubitemid 351171696)
11. National Comprehensive Cancer Center Guidelines. http://www.nccn.org.
12. Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003; 101:420-424. (Pubitemid 36077558)
13. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111:109-111. This is an update of the GHSG phase II study of standard dose rituximab in relapsed NLPHL. This series reports the longest progression-free survival (PFS) reached to date for the use of rituximab in this study population.
14. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003; 101:4285-4289.
15. Horning SJ, Bartlett NL, Breslin S, et al. Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD) [ASH Annual Meeting Abstracts]. Blood 2007; 110:644.
16. Azim HA Jr, Pruneri G, Cocorocchio E, et al. Rituximab in lymphocytepredominant Hodgkin disease. Oncology 2009; 76:26-29. This is the most recent publication investigating the role of rituximab in treatment-naive or relapsed NLPHL patients.
17. Keilholz U, Szelenyi H, Siehl J, et al. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti-CD20 monoclonal antibody) and interleukin-2. Leuk Lymphoma 1999; 35:641-642. (Pubitemid 30015668)
18. Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent nonHodgkin's lymphoma. J Clin Oncol 2002; 20:4261-4267. (Pubitemid 35191030)
19. Jacene HA, Kasamon YL, Ambinder RF, et al. Phase I/II dose-escalation study of tositumomab and Iodine I 131 tositumomab for relapsed/refractory classical or lymphocyte-predominant Hodgkin's lymphoma: feasibility and initial safety [ASH Annual Meeting Abstracts]. Blood 2008; 112:3059.